Di Yi Cai Jing·2026-02-26 13:14Core Viewpoint - Despite achieving record revenue, the growth rate of Baiyueze is slowing down [1] Group 1: Financial Performance - On February 26, 2025, the company reported total revenue of 38.205 billion yuan, a year-on-year increase of 40.4% [1] - The net profit attributable to the parent company reached 1.422 billion yuan, marking the first annual profit for the company [1] - Baiyueze's global sales reached 28.067 billion yuan, with a year-on-year growth of 48.8%, which is a slowdown compared to the doubling growth rates in 2023 and 2024 [1] Group 2: Product Performance - Baiyueze is the most widely approved BTK inhibitor globally, with approvals in over 75 markets [3] - In the U.S., Baiyueze remains the largest commercial market, contributing sales of 20.206 billion yuan, with a year-on-year growth of 45.5%, which is lower than the 107.5% growth in 2024 [3] - The second-highest revenue product, PD-1 monoclonal antibody Baizean, achieved global sales of 5.297 billion yuan, with a year-on-year increase of 18.6% [3] Group 3: Future Outlook - The company forecasts 2026 revenue to be between 43.6 billion yuan and 45 billion yuan, representing a growth rate of 14.12% to 17.79% compared to 2025 [3] - The company is working to reduce its reliance on Baiyueze by advancing multiple cornerstone products in late-stage clinical trials [3][4] - Baiyue's new product, Baiyueda, has received the first global marketing approval application in China for treating R/R MCL and is expected to receive regulatory decisions from the FDA in the first half of 2026 [4]